Rani Therapeutics Reports Initial Phase 1 Data Showing Oral RT‑114 Delivered Systemic Exposure Exceeding Matched Subcutaneous Administration, With Safety And Tolerability Consistent With GLP‑1/GLP‑2 Agonist Class

Loading news article.

Rani Therapeutics Reports Initial Phase 1 Data Showing Oral RT‑114 Delivered Systemic Exposure Exceeding Matched Subcutaneous Administration, With Safety And Tolerability Consistent With GLP‑1/GLP‑2 Agonist Class | WAPE

Rani Therapeutics Reports Initial Phase 1 Data Showing Oral RT‑114 Delivered Systemic Exposure Exceeding Matched Subcutaneous Administration, With Safety And Tolerability Consistent With GLP‑1/GLP‑2 Agonist Class

Article summary

Related companies

Comments —